Keith S. Reisinger

8.0k citations

108 papers · 6.0k indexed · 1 hit paper · h-index 41

Microbiology top 0.2%
- Bacterial Infections and Vaccines 32
Epidemiology top 0.2%
- Pneumonia and Respiratory Infections 32
- Influenza Virus Research Studies 22
- Respiratory viral infections research 22
- Virology and Viral Diseases 17
- Hepatitis B Virus Studies 15
- Herpesvirus Infections and Treatments 12
Otorhinolaryngology top 1%
Infectious Diseases top 1%
- Viral gastroenteritis research and epidemiology 10
Health top 1%

Co-authors: Mark M. Blatter Stan L. Block Frederick G. Hayden David I. Bernstein Regina Dutkowski Edward Rothstein Nancy L. Young David Ipe
Cited by: Microbiology Epidemiology Otorhinolaryngology
Partner nations: United States United Kingdom Japan

In The Last Decade

Keith S. Reisinger

107 papers receiving 5.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Keith S. Reisinger

Since Specialization

Citations

This map shows the geographic impact of Keith S. Reisinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith S. Reisinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith S. Reisinger more than expected).

Fields of papers citing papers by Keith S. Reisinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith S. Reisinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith S. Reisinger. The network helps show where Keith S. Reisinger may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Keith S. Reisinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Keith S. Reisinger Line = papers co-authored together Keith S. Reisinger links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Antibody Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents Roger Baxter,Keith S. Reisinger,S. Block,Allen Izu,Tatjana Odrljin,Peter Dull	2014	33
2	Antibody Persistence After Primary and Booster Doses of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents Roger Baxter,Keith S. Reisinger,S. Block,Sandra Percell,Tatjana Odrljin,Peter Dull,Igor Smolenov	2014	26
3	Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children Joanne M. Langley,Alfonso Carmona Martínez,Archana Chatterjee,Scott A. Halperin,Shelly McNeil,Keith S. Reisinger,Naresh Aggarwal,Li‐Min Huang,Ching‐Tien Peng,José García-Sicilia,Ignacio Salamanca de la Cueva,Fernando Cabañas,Consuelo Treviño‐Garza,M Weber,Manuel de la O,Vijayalakshmi Chandrasekaran,Walthère Dewé,Aixue Liu,Bruce L. Innis,Varsha Jain	2013	51
4	Safety and tolerability of zoster vaccine in adults ≥60 years old Alexander V. Murray,Keith S. Reisinger,Boris Kerzner,Jon E. Stek,Timothy A. Sausser,Jin Xu,William W. Wang,Ivan S. F. Chan,Paula W. Annunziato,Janie Parrino	2011	32
5	Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months James C. King,Manon Cox,Keith S. Reisinger,James Hedrick,Irene Graham,P. Patriarca	2009	58
6	A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents Lisa A. Jackson,Robert M. Jacobson,Keith S. Reisinger,Alessandra Anemona,Lisa Danzig,Peter Dull	2009	61
7	Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents Keith S. Reisinger,Stan L. Block,Eduardo Lazcano‐Ponce,Rudiwilai Samakoses,Mark T. Esser,Joanne Erick,Derek Puchalski,Katherine Giacoletti,Heather L. Sings,Suzanne Lukac,Frances B. Alvarez,Eliav Barr	2007	225
8	Safety, Tolerability and Immunogenicity of VAQTA Given Concomitantly versus Nonconcomitantly With Other Pediatric Vaccines in Healthy 12-Month-Old Children Fernando Guerra,Jacqueline Gress,Alan Werzberger,Keith S. Reisinger,Emmanuel B. Walter,Hassan Lakkis,Anthony D. Grosso,Carolee Welebob,Barbara J. Kuter	2006	9
9	Dose-Response Study of a Quadrivalent Measles, Mumps, Rubella and Varicella Vaccine in Healthy Children Henry R. Shinefield,Wendy R. Williams,Colin D. Marchant,Keith S. Reisinger,Tracy Stewart,H. Cody Meissner,Juan Guerrero,Stephanie O. Klopfer,F. Schödel,Barbara J. Kuter	2005	32
10	Measuring Antibody Responses to a Live Attenuated Influenza Vaccine in Children Min‐Shi Lee,Kutubuddin Mahmood,Lopa Adhikary,Marilyn J. August,Julie Cordova,Iksung Cho,George Kemble,Keith S. Reisinger,Robert Walker,Paul M. Mendelman	2004	43
11	Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination Michael E. Pichichero,Mark M. Blatter,Keith S. Reisinger,Christopher J. Harrison,Candice E. Johnson,Mark C. Steinhoff,Shelly Senders,Edward Rothstein,Paul Willems,Barbara J. Howe	2002	41
12	Oral oseltamivir treatment of influenza in childrenbreakdown → Richard J. Whitley,Frederick G. Hayden,Keith S. Reisinger,Nancy L. Young,Regina Dutkowski,David Ipe,Roger Mills,Penelope Ward	2001	541
13	An acellular pertussis vaccine in healthy adults: safety and immunogenicity Edward Rothstein,Edwin L. Anderson,Michael D. Decker,Gregory A. Poland,Keith S. Reisinger,Mark M. Blatter,Robert M. Jacobson,ChrisAnna M. Mink,Daniel Gennevois,Allen Izu,Faruk Sinangil,Andria Langenberg	1999	22
14	Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine Neal A. Halsey,Mark M. Blatter,Gerald Bader,M. L. Thoms,Field F. Willingham,J. Crossan O'Donovan,Lawrence C. Pakula,FLORENCE BERUT,Keith S. Reisinger,CARLTON MESCHIEVITZ	1997	24
15	Inactivated hepatitis A vaccine in childhood: implications for disease control DavidR. Nalin,Liliana Brown,Barbara J. Kuter,C Patterson,Brenda McGuire,Alan Werzberger,Mathuram Santosham,S. Block,Keith S. Reisinger,Barbara Watson,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	1993	14
16	Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17− to 24-month-old children Mary P. Glodé,L Joffe,Keith S. Reisinger,Mark M. Blatter,S Plotkin,Barbara Watson,Lauren Grossman,Basim I. Asmar,Michael J. Berry,Sidney Starobin,Gilbert R. Fisch,Jill Hackell,Bettina Sheip,BONNIE L. MCKEE	1992	22
17	Cefixime vs. cefaclor in the treatment of acute otitis media in infants and children Margaret A. Kenna,Charles D. Bluestone,Patricia A. Fall,JANET S. STEPHENSON,Marcia Kurs‐Lasky,F. P. Wucher,Mark M. Blatter,Keith S. Reisinger	1987	34
18	Wall Socket Electrical Burns: Relevance to Health Education? Thomas L. Young,Keith S. Reisinger	1980	12
19	Inaccuracy of the Clinitemp skin thermometer. Keith S. Reisinger,Joan Kao,Deborah M. Grant	1979	23
20	Effectiveness of Aggressive Follow-up on Navajo Infant Health and Medical Care Use Kenneth D. Rogers,R. Ernst,Ivan Shulman,Keith S. Reisinger	1974	8

About Keith S. Reisinger

Keith S. Reisinger is a scholar working on Microbiology, Epidemiology and Otorhinolaryngology, having authored 108 papers that have together received 6.0k indexed citations. Recurring topics across this work include Bacterial Infections and Vaccines (32 papers), Pneumonia and Respiratory Infections (32 papers), Influenza Virus Research Studies (22 papers), Respiratory viral infections research (22 papers), Virology and Viral Diseases (17 papers), Hepatitis B Virus Studies (15 papers), Herpesvirus Infections and Treatments (12 papers) and Viral gastroenteritis research and epidemiology (10 papers). The work is most often cited by research in Microbiology (1.1k citations), Epidemiology (4.5k citations) and Otorhinolaryngology (387 citations). Keith S. Reisinger has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Mark M. Blatter, Stan L. Block, Frederick G. Hayden, David I. Bernstein, Regina Dutkowski, Edward Rothstein, Nancy L. Young, David Ipe, Penelope Ward and Roger Mills.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact